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PHypertrophic Cardiomyopathy
elevance of Coronary Microvascular Flow
mpairment to Long-Term Remodeling and
ystolic Dysfunction in Hypertrophic Cardiomyopathy
acopo Olivotto, MD,* Franco Cecchi, MD,* Roberto Gistri, MD,* Roberto Lorenzoni, MD,‡
iampaolo Chiriatti, MD,§ Francesca Girolami, BSC,† Francesca Torricelli, BSC,†
aolo G. Camici, MD, FACC, FRCP¶
lorence, Lucca, Pescia, and Pisa, Italy; and London, United Kingdom
OBJECTIVES This study sought to evaluate whether the entity of microvascular dysfunction, assessed by
positron emission tomography (PET), predicts the long-term development of left ventricular
(LV) remodeling and systolic dysfunction in hypertrophic cardiomyopathy (HCM).
BACKGROUND A subgroup of patients with HCM developed LV dilation and systolic impairment. A causal
role of coronary microvascular dysfunction has been suggested as the underlying pathophys-
iological mechanism.
METHODS Fifty-one patients (New York Heart Association functional class I to II) were followed up for
8.1  2.1 years after measurement of resting and dipyridamole (Dip) myocardial blood flow
(MBF). Left ventricular systolic dysfunction was defined as an ejection fraction (LVEF) 50%.
RESULTS The Dip-MBF was blunted in HCM patients compared with a group of healthy control
patients (1.50  0.69 ml/min/g vs. 2.71  0.94 ml/min/g; p  0.001). At final evaluation,
11 patients (22%) had an LVEF 50%; in most (n  7), systolic dysfunction was associated
with a significant increase in LV cavity dimensions (5 mm) during follow-up. These 11
patients showed lower Dip-MBF than the 40 with preserved LV function (1.04  0.38
ml/min/g vs. 1.63  0.71 ml/min/g, respectively; p  0.001); Dip-MBF was particularly
blunted in five patients with clinical progression to severe heart failure symptoms or death
(Dip-MBF 0.89  0.15 ml/min/g). At multivariate analysis, the two independent predictors
of systolic dysfunction were Dip-MBF in the lowest tertile (1.1 ml/min/g; relative hazard,
7.5; p  0.038) and an end-diastolic LV dimension in the highest tertile (45 mm; relative
hazard, 12.3; p  0.031).
CONCLUSIONS Severe microvascular dysfunction is a potent long-term predictor of adverse LV remodeling
and systolic dysfunction in HCM. Our findings indicate microvascular dysfunction as a
potential target for prevention of disease progression and heart failure in HCM. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.10.050Cardiol 2006;47:1043–8) © 2006 by the American College of Cardiology Foundation
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oince its early descriptions, hypertrophic cardiomyopathy
HCM) has been characterized by a small, markedly hyper-
rophied, hypercontractile left ventricle (LV) (1). In a
ignificant minority of patients, however, progressive LV
ilation and impairment of systolic function may become
rominent clinical features, and lead to the so-called end-
tage phase (1–7). Although other causes may concur, this
rocess is thought to represent the consequence of recurrent,
iffuse myocardial ischemia attributable to coronary micro-
ascular dysfunction (8–11).
Using positron emission tomography (PET), we have
ecently shown that severe blunting of the coronary vasodi-
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esearch Council Clinical Sciences Centre, Hammersmith Hospital, Imperial Col-
ege, London, United Kingdom. Supported by grants from the Italian Ministry for
cientific and Technologic Research (MURST-COFIN 2004) and the Fondazione
nte Cassa di Risparmio di Firenze.p
Manuscript received May 27, 2005; revised manuscript received September 30,
005, accepted October 17, 2005.ator response to dipyridamole (Dip), reflecting microvas-
ular dysfunction, is a potent predictor of outcome in a
ohort of HCM patients, mostly related to heart failure and
ts complications (12). That work, however, did not address
he relationship between microvascular dysfunction and
ong-term changes in LV morphology and function, so that
uch an association remains unproven. Therefore, in the
ame HCM patient cohort, we aimed to assess whether the
everity of coronary microvascular dysfunction was predic-
ive of adverse long-term LV remodeling, systolic dysfunc-
ion, and progression to the end-stage phase.
ATIENTS AND METHODS
atients. The study cohort comprises 51 patients from a
arge regional HCM population, closely followed up at two
ommunity-based institutions in Tuscany. The baseline
eatures and clinical outcome of the study group have been
reviously reported (12). The diagnosis of HCM was based
n the echocardiographic evidence of myocardial hypertro-
hy (wall thickness 15 mm), in the absence of any other
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MBF Impairment and Systolic Dysfunction in HCM March 7, 2006:1043–8ardiac or systemic cause of LV hypertrophy (1). Exclusion
riteria were a history of hypertension or coronary artery
isease and severe congestive heart failure (New York Heart
ssociation [NYHA] functional class III to IV). All pa-
ients had Maron type II or III morphology (1). The mean
ge was 44  13 years, 36 (71%) patients were male, and 21
41%) patients were in NYHA functional class II. Fourteen
atients (27%) complained of typical angina and were
nrolled after documentation of angiographically normal
oronary arteries.
ontrol patients. The control group included 12 patients
ith an atypical chest pain syndrome (4 men) ages 51  8
ears (p  0.1 vs. patients). All had a normal physical
xamination, electrocardiogram, echocardiogram, treadmill
xercise test result, and coronary and LV angiograms.
able 1. Clinical and Echocardiographic Features of the 51 Stud
Overall Study Group
(n  51)
Lowest Te
<1.11
(
At the
Time of
PET Scan
At Final
Evaluation
At the
Time of
PET Sca
ge (yrs) 44  13 52  13 48  12
YHA functional class III to IV 0 9 (18%) 0
ith LV outflow obstruction
(30 mm Hg)
8 (16%) 4 (8%) 1 (6%)
ollow-up (yrs) — 8.1  2.1 —
eft atrial dimension (mm) 39  7 45  9* 41  9
aximum LV thickness
(mm)
22  5 21  5* 22  5
V end-diastolic diameter
(mm)
44  5 47  6* 46  5§
V end-systolic diameter
(mm)
27  6 30  8* 31  5‡
V end-diastolic volume (ml) 87  23 105  37* 100  25
hange in LV end-diastolic
volume (ml)
— 18  25 —
V end-systolic volume (ml) 28  15 40  15* 39  16
hange in LV end-systolic
volume (ml)
— 12  21 —
VEF (%) 69  12 59  14* 61  14
hange in LVEF
(% of basal value)
— 15  13 —
ith LV ejection fraction
50%
3 (6%) 11 (22%) 3 (17%)
ith LVEF 50% and
progression to NYHA
functional class III to IV
0 5 (10%) 0
p  0.05 versus same group at the time of PET scan. ‡p  0.05 versus patients in
Abbreviations and Acronyms
Dip  dipyridamole
HCM  hypertrophic cardiomyopathy
LV  left ventricle/ventricular
MBF  myocardial blood flow
NYHA  New York Heart Association
PET  positron emission tomographyDip  dipyridamole; EF  ejection fraction; LV  left ventricular; MBF  myocardi
omography.easurement of myocardial blood flow. All PET scans
ere performed at the Institute of Clinical Physiology, in
isa, between June 1990 and May 1993 (9,12). Regional
yocardial blood flow (MBF) was measured using PET
ith nitrogen-13-labeled ammonia under basal conditions
nd during near maximal hyperemia induced by Dip (0.56
g/kg, administered intravenously over 4 min) as previously
eported (9). For each MBF measurement, a dynamic
cquisition was started simultaneously with an intravenous
olus of nitrogen-13–labeled ammonia (0.25 mCi/kg of
ody weight). The Dip-MBF was measured 50 min after
he basal scan and 4 min after the end of Dip infusion,
ollowing the same protocol. Absolute regional MBF (in
l/min/g) was calculated as previously reported (9). The
tudy protocol was approved by the research ethics commit-
ees of each institution, and written consent was obtained
rom each patient.
linical and echocardiographic follow-up. Patients were
ollowed up for an average of 8.1  2.1 years after the PET
can with clinical and echocardiographic examinations. For
ach patient, we compared echocardiographic measure-
ents at the time of PET with the last available echocar-
iogram at the end of follow-up.
ients Based on Dip-MBF Values
f Dip-MBF
g/min
8)
Middle Tertile of Dip-MBF
1.11–1.60 ml/mg/min
(n  16)
Highest Tertile of Dip-MBF
>1.60 ml/mg/min
(n  17)
At Final
Evaluation
At the
Time of
PET Scan
At Final
Evaluation
At the
Time of
PET Scan
At Final
Evaluation
56  12 39  14 47  13 43  13 51  13
6 (33%)‡ 0 1 (6%) 0 2 (12%)
1 (6%) 2 (12%) 1 (6%) 5 (29%) 2 (12%)
7.7  2.3 — 7.9  2.1 — 8.5  2.1
47  11* 36  5 43  6* 39  7 44  7*
20  5 22  6 20  3 22  5 22  6
50  8‡* 43  5 45  5* 41  4 45  4*
36  9‡* 26  4 28  5* 24  5 27  5
125  43‡* 86  21 94  23* 75  16 93  17*
25  35 — 8  15 — 18  17
59  35‡* 23  9 31  14* 21  10 27  12
20  29 — 8  10 — 6  12
49  16‡* 73  7 64  10* 73  9 63  10*
19  15 — 12  12 — 13  12
9 (50%)‡ 0 1 (6%) 0 1 (6%)
5 (28%)‡ 0 0 0 0
tertiles. §p  0.05 versus patients in the highest tertile.y Pat
rtile o
ml/m
n  1
n
§

‡

‡

other
al blood flow; NYHA  New York Heart Association; PET  positron emission
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March 7, 2006:1043–8 MBF Impairment and Systolic Dysfunction in HCMStandard measurements of left atrial, LV end-diastolic,
nd end-systolic diameter were obtained in the paraster-
al long-axis view (13). In all patients, maximum LV wall
hickness values were in the basal or mid anterior septum
nd were measured in the same region of the LV wall
oth at the time of PET and at final evaluation. Obstruc-
ion of the LV outflow was considered present when a
eak outflow gradient of 30 mm Hg was present under
asal conditions (1). The LV ejection fraction (LVEF)
as measured in the standard four-chamber view by the
rea-length method (13). The LV systolic dysfunction
as defined as an LVEF 50%.
tatistical analysis. For the purpose of this study, patients
ere grouped into tertiles of Dip-MBF, and the relation-
hip of this ordinal variable with the development of systolic
ysfunction was assessed. Data were expressed as mean
alues  SD. For the comparison of normally distributed
ata, the Student t test was used for single comparisons;
ne-way analysis of variance was used for comparisons
mong tertiles of Dip-MBF, followed by the Bonferroni
ost-hoc test. Chi-square or Fisher exact tests, as appropri-
te, were used to compare non-continuous variables ex-
ressed as proportions. Relative hazard and 95% confidence
ntervals (CIs) were calculated using a stepwise forward Cox
roportional hazard regression model, with an entry prob-
bility for each variable set at 0.05. All p values are
wo-sided and considered significant when 0.05.
ESULTS
BF and baseline echocardiographic features. Resting
BF was not significantly different in patients and control
atients (0.84  0.31 ml/min/g vs. 1.00  0.23 ml/min/g,
espectively; p  0.10). By contrast, Dip-MBF was severely
lunted in HCM patients (1.50 0.69 ml/min/g vs. 2.71
.94 ml/min/g in the control patients; p  0.001). Table 1
hows patients’ features with respect to tertiles of Dip-
BF. At the time of PET, all patients were in NYHA
igure 1. Comparison of left ventricular (LV) ejection fraction at the time
f positron emission tomography (PET) and at final evaluation in the 51
tudy patients. Vertical bars indicate mean  SD for each group.unctional class I or II. On average, patients in the lower
A
Lertile of Dip-MBF (0.59 to 1.11 ml/min/g) had larger LV
avity dimensions and a lower EF compared with patients in
he other two tertiles (Table 1).
V remodeling and prevalence of systolic dysfunction. Av-
rage follow-up was 8.1  2.1 years. Compared with
aseline, final evaluation showed an overall increase in LV
nd-diastolic diameter (8 10%) and a decrease in LVEF
15  13%) (Table 1, Fig. 1). At initial evaluation, three
atients (6%) had an LVEF50%; eight additional patients
eveloped systolic dysfunction during follow-up. Thus, the
otal number of patients with LVEF 50% at final evalu-
igure 2. Stop frames of echocardiograms obtained at the time of the positron
mission tomography (PET) scan (age 33 years, panels A, C, and E) and at
nal evaluation (age 42 years, panels B, D, and F) in a hypertrophic
ardiomyopathy (HCM) patient with missense mutations of the myosin
eta-heavy chain and of the myosin binding protein C genes (Arg723Cys
nd Glu165Asp, respectively). Individual measurements are provided in
able 2 (Patient #1). Comparison of the two echocardiograms shows
rogression of LV cavity enlargement and systolic impairment, with
egression of septal hypertrophy. This patient had no functional limitation
t the time of PET; over nine years of follow-up he progressively developed
ongestive symptoms, and at final evaluation he was severely limited, with
yspnea on minimal effort. (A to D) Parasternal long-axis view. (E and F)
pical four-chamber view. *Interventricular septum. LA  left atrium,
V  left ventricle.
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MBF Impairment and Systolic Dysfunction in HCM March 7, 2006:1043–8tion was 11 (22%); in this group, the average decrease in
VEF from baseline was 27  11% (Table 2). In most
n  7), development of systolic dysfunction was associated
ith a 5 mm increase in LV end-diastolic diameter
average, 9 mm); however, four patients showed little
ariation (5 mm; average, 3 mm) (Table 2).
At final evaluation, 5 of the 11 patients with LVEF
50% progressed to NYHA functional class III to IV,
ncluding two patients who eventually died of heart failure
nd two who have been evaluated for cardiac transplantation
Fig. 2, Table 2). Among these five patients, the final LV
nd-diastolic dimension ranged from 44 to 68 mm, and the
VEF from 25% to 46%. Of note, only two patients already
ad an LVEF 50% at the time of PET (Table 2).
elevance of MBF impairment to LV remodeling. Av-
rage Dip-MBF was significantly lower in the 11 patients in
hom LV systolic dysfunction developed, compared with
he 40 with preserved LV function (1.04  0.38 ml/min/g
s. 1.63  0.71 ml/min/g, respectively; p  0.001). The
BF impairment was particularly severe among the five
atients whose condition progressed to NYHA functional
lass III to IV or who died (Dip-MBF, 0.89  0.15
l/min/g). Prospectively, patients in the lowest tertile of
ip-MBF (1.11 ml/min/g) showed a greater increase in
V dimensions and decrease in LVEF during follow-up as
ompared with each other tertile, even though there was
onsiderable individual variability in each group (Table 1,
ig. 3). Specifically, 9 of the 11 patients with systolic
ysfunction belonged to the lowest Dip-MBF tertile, com-
ared with only 2 of the 40 patients with preserved LV
unction (Table 2). After exclusion of the three patients
ith LVEF 50% at initial evaluation, the positive and
egative predictive values of Dip-MBF 1.11 ml/min/g to
oretell the development of systolic dysfunction were 40%
nd 94%, respectively.
In a multivariate Cox regression model including age,
ender, NYHA functional class, initial LV dimensions,
aximum LV thickness, and magnitude of LV outflow
able 2. Individual Features of 11 Patients With Systolic Dysfun
Patient Gender
Basal MBF
(ml/mg/min)
Dip-MBF
(ml/mg/min)
Tertile of
Dip-MBF At P
1 M 0.71 1.06 Lowest 3
2 M 0.85 0.91 Lowest 3
3 M 0.65 0.74 Lowest 5
4 M 0.50 0.68 Lowest 6
5 M 0.87 0.89 Lowest 6
6 M 1.09 0.82 Lowest 5
7 M 0.46 1.05 Lowest 5
8 M 0.60 0.76 Lowest 5
9 M 0.68 1.07 Lowest 4
10 F 0.64 1.47 Middle 5
11 F 0.61 1.99 Highest 4
verall 0.70  0.18 1.04  0.38 51 radient, the only two independent long-term predictors of aV systolic dysfunction were a Dip-MBF in the lowest
ertile (relative hazard, 7.5; 95% CI: 1.1 to 50.4; p  0.038)
nd an end-diastolic LV dimension in the highest tertile
45 mm; relative hazard, 12.3; 95% CI: 1.2 to 121.5; p 
.031).
ISCUSSION
BF impairment andLV systolic dysfunction inHCM. The
ain finding of the present study was that severe impair-
ent of the coronary vasodilator response to Dip is strongly
ssociated with long-term adverse LV remodeling and
ystolic dysfunction in HCM patients. Over an average
ollow-up8 years, patients with a Dip-MBF in the lowest
ertile showed a 7.5-fold higher risk of developing systolic
ysfunction (defined as an LVEF 50%) compared with
he other two tertiles. The only other independent predictor
f systolic dysfunction was a baseline end-diastolic LV
imension in the highest tertile (45 mm), possibly sug-
esting an early propensity toward cavity dilation.
We previously described the association of an impaired
ip-MBF with increased LV dimensions and reduced
ractional shortening in HCM patients studied cross-
ectionally (14). Indeed, the baseline data of the present
tudy are consistent with a certain degree of LV remodeling
efore study enrolment among patients in the lowest tertile
f Dip-MBF. However, we now show that even in the
resence of a normal LV cavity size and function, the degree
f microvascular dysfunction is a potent predictor of remod-
ling and systolic impairment. Indeed, with a negative
redictive value as high as 94%, a Dip-MBF in the lowest
ertile seemed to be a necessary prerequisite for long-term
mpairment of systolic dysfunction in HCM patients,
hereas a relatively preserved vasodilator capacity showed a
owerful protective effect. Thus, PET studies of microvas-
ular function potentially represent a valuable tool for the
dentification of HCM patients at risk of severe disease
rogression, even in individuals with no or mild symptoms
at Final Evaluation
(yrs) Atrial Fibrillation
NYHA Functional
Class
OutcomeFinal At PET Final At PET Final
42 0 Paroxysmal I III/IV Evaluation
for Tx
42 0 Paroxysmal II IV Awaiting Tx
59 Chronic Chronic II III HF death
72 Paroxysmal Chronic II III HF death
77 Paroxysmal Paroxysmal I III Embolic
stroke
61 0 0 II II Alive
59 0 Chronic I II Alive
64 Chronic Chronic II II Alive
51 0 0 II II ICD
65 0 0 I II Alive
58 0 0 I I Alive
59  11 1.5  0.5 2.4  0.8
Continued on next pagection
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March 7, 2006:1043–8 MBF Impairment and Systolic Dysfunction in HCMhe face of preliminary evidence that certain pharmacologic
gents, such as verapamil and angiotensin-converting enzyme
nhibitors, may positively influence the coronary microcircula-
ion (15,16).
Of note, some patients in the lowest tertile of Dip-MBF
lready had evidence of relative LV dilation and somewhat
educed systolic function at study entry, which may have
mphasized the differences observed during follow-up com-
ared with the other tertiles. For those patients, we could
ot quantify the morphologic change occurring before
nrolment, nor its possible relevance to coronary microvas-
ular function (e.g., because of elevated filling pressures) (8).
evertheless, when initial LV end diastolic dimensions and
VEF were taken into account in a multivariate model,
igure 3. Comparison of left ventricular (LV) end-diastolic volume and
jection fraction at the time of positron emission tomography (PET) and
t final evaluation according to tertiles of dipyridamole myocardial blood
ow. Vertical bars indicate mean  SD for each group. *p  0.05 versus
able 2. Continued
Left Atrium
(mm)
Maximum LV
Thickness
(mm)
LV EDD/ESD
(mm)
At
PET Final
At
PET Final At PET Final
39 42 17 12 51/36 68/55
49 55 33 30 50/31 58/42
61 70 24 22 49/38 51/39
42 51 18 16 52/39 55/39
49 49 24 24 40/34 44/32
36 44 17 15 41/33 44/35
40 47 22 17 48/35 53/40
62 73 20 20 53/39 58/46
32 40 26 18 47/27 65/50
33 45 21 17 45/28 50/37
37 40 20 18 40/29 45/28
44  10 50  12 22  5 19  5 47  5/33  4 53  9/41  7
DD  end-diastolic dimension; ESD  end-systolic dimension; FU  follow-up;
VOT  LV outflow tract; MBF  myocardial blood flow; NYHA  New York
ransplantation; other abbreviations as in Table 1.o
ame group at the time of PET scan; †p  0.05 versus patients in the
ighest tertile; ‡p  0.05 versus patients in other tertiles.ip-MBF remained a powerful independent predictor of
ystolic dysfunction in our cohort.
nd-stage phase progression. The most dramatic clinical
onsequence of LV remodeling in HCM is represented
y progression to the so-called “end-stage” phase, which
ay be difficult to distinguish from a primary dilated
ardiomyopathy, is associated with severe clinical signs of
eart failure and may require heart transplantation (1–7).
n the present study, all patients with such progression
ad an extremely impaired vasodilator response to Dip,
ot exceeding and often below the resting MBF values
easured in healthy control patients. Thus, although
esser degrees of LV remodeling also occurred in patients
ith relatively preserved Dip-MBF, severe degrees of
ystolic dysfunction, LV dilation, and clinical progression
o heart failure were confined to patients with extreme
mpairment of flow.
We acknowledge that the prevalence of end-stage
rogression in our study cohort overestimates that in the
eneral HCM population. Indeed, the prevalence of
ystolic dysfunction was found to be 5% in most reports
1). In the overall Florence HCM database, which
ncludes more than 500 patients, 13% of the patients
rogressed to an end-stage phase over an average
ollow-up of about 10 years (F. Cecchi and I. Olivotto,
npublished observation, 2005) compared with 22% in
he present study. Such a discrepancy suggests an unde-
ned selection bias that led to a preferential inclusion of
atients with progressive disease, despite the fact that
ndividuals with overt heart failure were excluded by the
tudy protocol.
athophysiology of LV remodeling in HCM. The most
ikely mechanism by which microvascular dysfunction is
mplicated in LV remodeling is represented by substantial
owering of the ischemic threshold, increased likelihood
LV EDV/ESV
(ml)
LV Ejection
Fraction
(%)
SAM-Related
LVOT
Gradient
(mm Hg)
At PET Final
At
PET Final
At
PET Final
124/54 239/147 56 32 0 0
118/38 167/79 68 46 23 0
113/62 124/66 45 39 0 0
130/66 147/66 50 40 0 0
70/47 82/61 32 25 45 25
74/44 88/51 41 34 0 0
108/51 135/70 53 40 0 0
135/66 167/97 51 34 0 0
102/27 216/118 74 38 0 0
92/30 118/58 68 46 0 0
70/32 85/32 54 45 0 0
 24/47  14 140  55/76  34 54  12 38  7 2/11 1/11
heart failure; ICD  implantable cardioverter-defibrillator; LV  left ventricular;
t Association; SAM  systolic anterior motion of the mitral valve; Tx  cardiac103
HF f recurrent ischemic damage to the myocardium, re-
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MBF Impairment and Systolic Dysfunction in HCM March 7, 2006:1043–8lacement fibrosis, chamber dilation, and loss of contrac-
ile function (2,3,5,9 –12). A similar process is thought to
ccur in patients surviving acute myocardial infarction, in
hom persistent microvascular dysfunction after success-
ul reperfusion represents a powerful predictor of LV
ilation and heart failure (17). Of note, although the
bsolute change in LVEF and cavity dimensions was
reater in the lowest tertile of Dip-MBF, considerable
ariability existed within each tertile. This is consistent
ith the fact that the individual ischemic burden may
ary considerably based on the relevance of triggers such
s exercise, arrhythmias, and outflow obstruction (18 –
9). In addition, pathophysiological mechanisms such as
rimary fibrosis (20), apoptosis (21), and inappropriately
ncreased adrenergic stimulation (22) may add to inter-
ndividual variability.
Finally, although the development of systolic dysfunc-
ion was generally associated with progressive LV dila-
ion in our cohort, a minority of patients with progressive
oss of systolic function had only a very limited increase in
V cavity size. A potential explanation for this is
epresented by extensive and diffuse fibrous replacement
f the myocardium, leading to loss of contractile function
ithout apparent remodeling of the LV (6). Indeed,
ystolic dysfunction is not uncommon in the context of a
estrictive evolution of HCM, in which LV cavity size is
ormal or reduced.
ONCLUSIONS
evere microvascular dysfunction is a potent long-term
redictor of LV adverse remodeling and systolic dysfunction
n HCM, which can be identified well before irreversible
orphologic and functional changes occur. Thus, our find-
ngs indicate microvascular dysfunction as a potential target
or the prevention of disease progression and heart failure in
CM.
eprint requests and correspondence: Dr. Iacopo Olivotto,
entro di Riferimento per le Cardiomiopatie, Cardiologia San
uca, Azienda Ospedaliera Universitaria Careggi, Viale Pieraccini
9, 50134 Firenze, Italy. E-mail: olivottoi@ao-careggi.toscana.it.
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